Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

Alterations in the mesenchymal-epithelial transition factor (MET) gene are critical drivers of non-small cell lung cancer (NSCLC). In recent years advances in precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients. These alterations include MET...

Full description

Saved in:
Bibliographic Details
Main Authors: Huijing Feng, Yang Xia, Wenxian Wang, Chunwei Xu, Qian Wang, Zhengbo Song, Ziming Li, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lyu, Liyun Miao, Lingfeng Min, Gen Lin, Long Huang, Jingping Yuan, Zhansheng Jiang, Xingxiang Pu, Chuangzhou Rao, Dongqing Lyu, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Qi Mei, Hui Guo, Qian Chu, Rui Meng, Xuewen Liu, Jingxun Wu, Jin Zhou, Zhengfei Zhu, Weiwei Pan, Fei Pang, Meizhen Hu, Kai Wang, Fan Wu, Bingwei Xu, Ling Xu, Liping Wang, Youcai Zhu, Jisheng Li, Yanru Xie, Xinqing Lin, Jing Cai, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jing Kang, Jiatao Zhang, Chao Zhang, Wenbin Gao, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Yue Hao, Zheng Wang, Bing Wan, Donglai Lyu, Xiaodong Jiao, Lin Shi, Gang Lan, Shengjie Yang, Yanhong Shang, Yina Wang, Bihui Li, Gang Jin, Kang Zheng, Jun Ma, Wenfeng Li, Zhang Zhang, Zhongwu Li, Yuan Li, Zhefeng Liu, Xuelei Ma, Nong Yang, Lin Wu, Qiming Wang, Guansong Wang, Zhuan Hong, Jiandong Wang, Meiyu Fang, Yong Fang, Xixu Zhu, Yi Shen, Ke Wang, Xiubao Ren, Yiping Zhang, Shenglin Ma, Junping Zhang, Yong Song, Wenfeng Fang, Yuanzhi Lu
Format: Article
Language:English
Published: China Anti-Cancer Association 2025-03-01
Series:Cancer Biology & Medicine
Subjects:
mesenchymal-epithelial transition factor
met exon 14 skipping mutation
met amplification
non-small cell lung cancer
precision medicine
targeted therapy
tyrosine kinase
Online Access:https://www.cancerbiomed.org/content/22/3/237
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alterations in the mesenchymal-epithelial transition factor (MET) gene are critical drivers of non-small cell lung cancer (NSCLC). In recent years advances in precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients. These alterations include MET exon 14 skipping mutations (MET exon 14 skipping), MET gene amplifications, MET point mutations (primarily kinase domain mutations), and MET protein overexpression. Accurate identification of these alterations and appropriate selection of patient populations and targeted therapies are essential for improving clinical outcomes. The East China Lung Cancer Group, Youth Committee (ECLUNG YOUNG, Yangtze River Delta Lung Cancer Cooperation Group) has synthesized insights from China’s innovative drug development landscape and clinical practice to formulate an expert consensus on the diagnosis and treatment of NSCLC patients with MET alterations. This consensus addresses key areas, such as optimal testing timing, testing methods, testing strategies, quality control measures, and treatment approaches. By offering standardized recommendations, this guidance aims to streamline diagnostic and therapeutic processes and enhance clinical decision-making for NSCLC with MET alterations.
ISSN:2095-3941

Similar Items